Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Peripheral Endocannabinoid System Dysregulation in First-Episode Psychosis
Miquel Bioque, Borja García‐Bueno, Karina S. MacDowell, et al.
Neuropsychopharmacology (2013) Vol. 38, Iss. 13, pp. 2568-2577
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
María S. García‐Gutiérrez, Francisco Navarrete, Ani Gasparyan, et al.
Biomolecules (2020) Vol. 10, Iss. 11, pp. 1575-1575
Open Access | Times Cited: 210
Cannabis and Psychosis: a Critical Overview of the Relationship
Charles Ksir, Carl L. Hart
Current Psychiatry Reports (2016) Vol. 18, Iss. 2
Closed Access | Times Cited: 169
Inflammation in schizophrenia: A question of balance
Juan C. Leza, Borja García‐Bueno, Miquel Bioque, et al.
Neuroscience & Biobehavioral Reviews (2015) Vol. 55, pp. 612-626
Closed Access | Times Cited: 170
Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics
Chi‐Yu Lai, Elizabeth Scarr, Madhara Udawela, et al.
World Journal of Psychiatry (2016) Vol. 6, Iss. 1, pp. 102-102
Open Access | Times Cited: 143
Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use
Hannah Myles, Nicholas Myles, Matthew Large
Australian & New Zealand Journal of Psychiatry (2015) Vol. 50, Iss. 3, pp. 208-219
Closed Access | Times Cited: 125
Endocannabinoid System Components as Potential Biomarkers in Psychiatry
Francisco Navarrete, María S. García‐Gutiérrez, Rosa Jurado‐Barba, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 104
Measuring Disturbance of the Endocannabinoid System in Psychosis
Amedeo Minichino, Morwenna Senior, Natascia Brondino, et al.
JAMA Psychiatry (2019) Vol. 76, Iss. 9, pp. 914-914
Open Access | Times Cited: 95
Social Stress and Psychosis Risk: Common Neurochemical Substrates?
Romina Mizrahi
Neuropsychopharmacology (2015) Vol. 41, Iss. 3, pp. 666-674
Open Access | Times Cited: 94
Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors
Naielly Rodrigues da Silva, Felipe V. Gomes, Andreza B. Sonego, et al.
Pharmacological Research (2020) Vol. 156, pp. 104749-104749
Open Access | Times Cited: 72
Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis
Deepak Cyril D’Souza, Marta Di Forti, Suhas Ganesh, et al.
The World Journal of Biological Psychiatry (2022) Vol. 23, Iss. 10, pp. 719-742
Closed Access | Times Cited: 63
New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Berhanu Geresu Kibret, Hiroki Ishiguro, Yasue Horiuchi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 975-975
Open Access | Times Cited: 45
Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia
Marc Fakhoury
Molecular Neurobiology (2016) Vol. 54, Iss. 1, pp. 768-778
Closed Access | Times Cited: 70
Microglial Cells as a Link between Cannabinoids and the Immune Hypothesis of Psychiatric Disorders
Sabrina F. Lisboa, Felipe V. Gomes, Francisco Silveira Guimarães, et al.
Frontiers in Neurology (2016) Vol. 7
Open Access | Times Cited: 65
Endocannabinoid system in psychotic and mood disorders, a review of human studies
Ranjini Garani Ramesh, Jeremy J. Watts, Romina Mizrahi
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2020) Vol. 106, pp. 110096-110096
Open Access | Times Cited: 51
Cannabis Pharmacogenomics: A Path to Personalized Medicine
Mariana Babayeva, Zvi G. Loewy
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 4, pp. 3479-3514
Open Access | Times Cited: 17
Association between neutrophil to lymphocyte ratio and inflammatory biomarkers in patients with a first episode of psychosis
Miquel Bioque, Vicent Llorca-Bofí, S. Salmeròn, et al.
Journal of Psychiatric Research (2024) Vol. 172, pp. 334-339
Closed Access | Times Cited: 6
Elevation of Plasma 2-Arachidonoylglycerol Levels in Alzheimer’s Disease Patients as a Potential Protective Mechanism against Neurodegenerative Decline
Claudia Altamura, Mariacarla Ventriglia, Maria Giulia Martini, et al.
Journal of Alzheimer s Disease (2015) Vol. 46, Iss. 2, pp. 497-506
Closed Access | Times Cited: 54
Effect of cannabidiol on endocannabinoid, glutamatergic and GABAergic signalling markers in male offspring of a maternal immune activation (poly I:C) model relevant to schizophrenia
Ashleigh L. Osborne, Nadia Solowij, Ilijana Babic, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2019) Vol. 95, pp. 109666-109666
Closed Access | Times Cited: 51
Cannabinoids and Schizophrenia: Risks and Therapeutic Potential
Marc W. Manseau, Donald Goff
Neurotherapeutics (2015) Vol. 12, Iss. 4, pp. 816-824
Open Access | Times Cited: 50
Systems biology approaches to study lipidomes in health and disease
Marina Amaral Alves, Santosh Lamichhane, Alex M. Dickens, et al.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2020) Vol. 1866, Iss. 2, pp. 158857-158857
Open Access | Times Cited: 47
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
Daniela Navarro, Ani Gasparyan, Francisco Navarrete, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4764-4764
Open Access | Times Cited: 24
Immune system: A possible nexus between cannabinoids and psychosis
Paula Suárez‐Pinilla, José López-Gil, Benedicto Crespo‐Facorro
Brain Behavior and Immunity (2014) Vol. 40, pp. 269-282
Closed Access | Times Cited: 51
Biomarkers for drug development in early psychosis: Current issues and promising directions
Donald Goff, Klaus Romero, Jeffrey Paul, et al.
European Neuropsychopharmacology (2016) Vol. 26, Iss. 6, pp. 923-937
Open Access | Times Cited: 45
New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders
María Scherma, Paolo Masia, Matteo Luca Deidda, et al.
Medicines (2018) Vol. 5, Iss. 4, pp. 107-107
Open Access | Times Cited: 39
A systematic review of phytocannabinoid exposure on the endocannabinoid system: Implications for psychosis
Maya R. Jacobson, Jeremy J. Watts, Isabelle Boileau, et al.
European Neuropsychopharmacology (2019) Vol. 29, Iss. 3, pp. 330-348
Closed Access | Times Cited: 39
Page 1 - Next Page

Scroll to top